JAK2
52 programs · 51 companies
Programs
52
Companies
51
Active Trials
29
Targeting JAK2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| GMA-5010 | Genmab | Phase 3 | MigraineRCC | |
| Teravorutinib | Illumina | Phase 2 | AngelmanALL | |
| AXS-4984 | Axsome | Preclinical | CFCKD | |
| Capirapivir | TG Therapeutics | Approved | PVRB | |
| Zenorelsin | Disc Medicine | NDA/BLA | LNPsoriasis | |
| IRO-8712 | Disc Medicine | Preclinical | RA | |
| Sovainavolisib | Biomea Fusion | Preclinical | Pancreatic Ca | |
| Rilucapivasertib | Ventyx Bio | Phase 2/3 | NASH | |
| Voxazasiran | Vir Bio | Phase 2/3 | ThymomaUC | |
| FHT-3384 | Foghorn | NDA/BLA | Urothelial CaFTD | |
| Kemanaritide | Fate Ther | Phase 3 | ACC | |
| Mirilucimab | Uniqure | NDA/BLA | RB | |
| GUS-IIT-662 | Gustave Roussy | Preclinical | PTSD | |
| SEO-IIT-994 | Seoul Natl Univ Hosp | Phase 2 | GBM | |
| MSK-IIT-725 | MSKCC Breast Svc | Phase 2/3 | Asthma | |
| Zanulemzoparlimab | Cerevel (AbbVie) | Phase 1 | NBNSCLC | |
| Lisozumab | EQRx | NDA/BLA | RBLN | |
| Zorinesiran | ArriVent BioPharma | Phase 2/3 | PompeCLL | |
| Teratenlimab | Larimar | Preclinical | FTDEndometrial Ca | |
| ENT-2952 | Enanta | Phase 3 | CTCLThymoma | |
| FLA-9061 | Flagship Labs | NDA/BLA | SCDEwing Sarcoma | |
| PRQ-3485 | ProQR Therapeutics | NDA/BLA | Crohn's | |
| KAL-3067 | Kala Pharma | Phase 2/3 | TTR Amyloidosis | |
| Gelirapivir | NGM Biopharm | NDA/BLA | HCC | |
| Dararapivir | Acceleron (Merck) | Phase 2/3 | Crohn'sFL | |
| VES-5139 | Vesalius | Phase 1/2 | SMACSU | |
| Mavucagene | BigHat Bio | NDA/BLA | CLL | |
| IMM-2921 | Immunai | Phase 1/2 | FTD | |
| INS-9902 | Insitro | Phase 1/2 | AsthmaHuntington's | |
| VAL-6020 | Valo Health | Phase 2/3 | Urothelial CaAS | |
| CAP-2067 | Capsida Bio | Phase 2/3 | Melanoma | |
| IVE-1037 | Iveric (Astellas) | Phase 2 | SLEObesity | |
| PCV-5987 | Vaxcyte | Phase 2/3 | RSV | |
| Niracilimab | CymaBay (Gilead) | Phase 1 | Narcolepsy | |
| Zorisotorasib | Ikena Onc | Approved | HSHNSCC | |
| Nidacilimab | Aurobindo | Approved | PsoriasisADPKD | |
| Adagraderotide | Gloria Bio | Phase 1/2 | HSIgAN | |
| VEC-8813 | Vectura (PMI) | Phase 3 | MCCCrohn's | |
| Capiinavolisib | Adaptimmune | Phase 2/3 | Narcolepsy | |
| Kemavorutinib | Exact Sciences | Approved | SCD | |
| Daranesiran | Basilea Pharma | Approved | IPF | |
| OBS-7968 | Obseva (XOMA) | Approved | Huntington's | |
| NTC-7741 | NTC Pharma | NDA/BLA | WMCSU | |
| Bemaderotide | Summit Therapeutics | Phase 2/3 | Ovarian CaUrothelial Ca | |
| REA-6162 | Reaction Biology | Preclinical | FTD | |
| BIO-8234 | Biogenesis Bago | Preclinical | Urothelial CaFSGS | |
| CTT-403 | CTTQ Pharma | Phase 1 | Endometrial CaHemophilia A | |
| 600-2840 | Humanwell Healthcare | Phase 1 | MMDravet | |
| Talarapivir | Agilent Technologies | Phase 2/3 | ACC | |
| Daralemzoparlimab | Zambon | Phase 1/2 | Gastric CaPancreatic Ca | |
| Ribozumab | Theramex | Phase 1/2 | MCL | |
| ZHE-740 | Zhejiang Jiuzi | Approved | PBCOCD |